Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of selenium and triamcinolone acetonide. Selenium is an essential trace element with antioxidant properties, often used as a dietary supplement or adjunct in various conditions due to its role in reducing oxidative stress. Triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive effects, commonly used topically or by injection for inflammatory skin diseases and autoimmune conditions. The combination has been studied experimentally as a topical therapy for oral lichen planus (OLP), where the antioxidant effect of selenium may complement the anti-inflammatory action of triamcinolone acetonide to improve lesion healing and symptom control[1]. The mechanism involves reduction of local inflammation (triamcinolone) and mitigation of oxidative stress (selenium).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on selenium + triamcinolone acetonide.